Subscribe
piotr-zajda-shutterstock-com
Piotr Zajda / Shutterstock.com
30 November 2015Americas

Nautilus’s Supreme Court petition bolstered by tech companies’ support

A group of technology companies has urged the US Supreme Court to re-hear the Nautilus v Biosig case, arguing that the US Court of Appeals for the Federal Circuit failed to apply the “reasonable certainty” standard for determining whether a patent claim is indefinite.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
US Supreme Court knocks back two medical device disputes
1 December 2015   The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Medtech
US Supreme Court knocks back two medical device disputes
1 December 2015   The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.

More on this story

Medtech
US Supreme Court knocks back two medical device disputes
1 December 2015   The US Supreme Court has rejected both Nautilus’s and Covidien’s attempt to reverse patent infringement judgments in two separate disputes centring on medical devices.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims